Results 51 to 60 of about 308,881 (201)

Identification and Structural Characterization of Viroporins from Deadly Hemorrhagic Viruses

Viruses
Crimean–Congo hemorrhagic fever virus (CCHF-V) and Ebola virus are lethal pathogens that cause widespread outbreaks of hemorrhagic fever. Both diseases can be transmitted through contact with the bodily fluids of infected individuals, but as an arbovirus,
Hiya Lahiri, Kingshuk Basu, Isaiah T. Arkin   +2 more
doaj   +1 more source

Re-emerging infectious diseases: Ebola hemorrhagic fever [PDF]

Romanian Journal of Military Medicine, 2014
The spring of 2014 has brought a new calamity, the exotic infectious disease: Ebola Hemorrhagic Fever, which is caused by a highly contagious and pathogenic virus, transmitted directly by interpersonal contact or indirectly by common usage of objects ...
Lucia E. Ionescu, Gabriela V. Dumitrescu, Viorel Ordeanu   +2 more
doaj  

Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems

Advanced Science, Volume 13, Issue 39, 13 July 2026.
By integrating data from in vitro, ex vivo, and in vivo models, our research identifies the MARV glycoprotein as a remarkable hemorrhagic factor, filling a major gap in this important field. It also provides practical experimental tools for the basic research on viral pathogenesis and applied research aimed at antiviral intervention for hemorrhagic ...
Ting Yao, Hang Liu, Yanfeng Yao, Wei Deng, Jiawen Sun, Zhenyu Kang, Ashaq Ali, Chao Shan, Zhiming Yuan, Fei Deng, Hualin Wang, Yun‐Jia Ning   +11 more
wiley   +1 more source

Secreted Nonstructural Protein 3 is a Pathogenic Determinant of Orbivirus

Advanced Science, Volume 13, Issue 42, 28 July 2026.
This study uncovers a conserved PIP2‐dependent secretory pathway of orbivirus NS3 that induces vascular leakage. Pharmacological disruption of PIP2‐NS3 interaction significantly reduces viral pathogenicity and provides protective efficacy in murine models, establishing PIP2‐mediated NS3 secretion as both a key virulence determinant and a promising ...
Junyong Guan, Dong Zhou, Ran Shao, Xing Liu, Jin Peng, Yingran Huang, Shuhui Qi, Cankun Xi, Menghang Wang, Bin Sun, Yinglin Qi, Xin Yin   +11 more
wiley   +1 more source

Short communication: a cluster of Marburg virus disease involving an infant.

, 2002
A noteworthy cluster of six cases of Marburg haemorrhagic fever (MHF) was identified in the Democratic Republic of Congo. One of the cases is the first infant Marburg fever patient ever documented. Three of six cases presented surprisingly mild symptoms.
Borchert, M., Muyembe-Tamfum, Jean Jacques, Van der Stuyft, P., Colebunders, Robert, Libande, M., Sabue, M., Van Der Stuyft, Patrick, Muyembe-Tamfum, J. J., Libande, Modeste, Sabue, Mulangu, Borchert, Matthias, Colebunders, R., Muyembe-Tamfum, Jean-Jacques   +12 more
core   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

What we know about ocular manifestations of Ebola

Clinical Ophthalmology, 2014
Majid Moshirfar,1 Carlton R Fenzl,2 Zhan Li3 1Department of Ophthalmology, Francis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; 2John A Moran Eye Center, University of Utah, Salt Lake City, UT, USA ...
Moshirfar M, Fenzl CR, Li Z
doaj  

The Problematic Diseases of viral Hemorrhagic Fever: Insights into Ebola, Marburg, and Dengue Fever Viruses [PDF]

ERU Research Journal
Viral Hemorrhagic Fever Diseases are critical health problems worldwide. Several outbreaks of hemorrhagic fever diseases have emerged in the last few years in different countries, particularly in tropical and subtropical regions of Africa, raising ...
Tharwat El-khamissy, Mohammed Abdo
doaj   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Infectious Disease Response in Tanzania: Enhanced Strategies From the 2023 to 2025 Marburg Outbreaks

Public Health Challenges, Volume 5, Issue 2, June 2026.
ABSTRACT The 2023 Marburg virus disease (MVD) outbreak in Tanzania, which resulted in nine confirmed cases and six deaths (case fatality rate [CFR]: 66.7%), served as a critical stress test of the national health system, revealing significant gaps in outbreak preparedness across surveillance, laboratory capacity, and infection prevention and control ...
Huda Haque, Faraan O. Rahim, Sameer Abbasi, Nam Nguyen, Erick Mahatara, Alison Jang, Ntuli A. Kapologwe   +6 more
wiley   +1 more source